

Prior Authorization
JOHNS HOPKINS HEALTH PLANS Taltz - Priority Partners MCO
This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to Johns Hopkins Health Plans at 1-410-424-4607 . Please contact Johns Hopkins Health Plans at 1-888-819-1043 with questions regarding the Prior Authorization process. When conditions are met, we will authorize the coverage of Taltz - Priority Partners MCO.

Drug Name (select from list of drugs shown) Taltz (ixekizumab)

Quantity	Frequency	Strength
Route of Administration	Expected Length of Therapy	

Patient Information	
Patient Name:	_____
Patient ID:	_____
Patient Group No.:	_____
Patient DOB:	_____
Patient Phone:	_____

Prescribing Physician	
Physician Name:	_____
Physician Phone:	_____
Physician Fax:	_____
Physician Address:	_____
City, State, Zip:	_____

Diagnosis: _____	ICD Code: _____
-------------------------	------------------------

Comments: _____

Please circle the appropriate answer for each question.	
1. Has the plan authorized this medication in the past for this patient (i.e., previous authorization is on file under this plan)?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: The use of physician samples, or manufacturer product discounts, does not guarantee coverage under the provisions of the medical and/or pharmacy benefit. All pertinent criteria must be met in order to be eligible for benefit coverage.	
[If yes, skip to question 25.]	
2. Has the patient previously received biologic therapy?	<input type="checkbox"/> Y <input type="checkbox"/> N

[If yes, skip to question 5.]	
3. Has the patient undergone tuberculosis screening within the past year?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If no, no further questions.]	
4. Does the patient have an active tuberculosis infection prior to starting the requested biologic therapy?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If yes, no further questions.]	
5. Does the patient have a diagnosis of active psoriatic arthritis?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If no, skip to question 8.]	
6. Has the patient tried and had insufficient response to at least two disease-modifying antirheumatic drugs (DMARDs) including methotrexate?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If yes, skip to question 10.]	
7. Does the patient have a contraindication to at least two disease-modifying antirheumatic drugs (DMARDs) including methotrexate?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If yes, skip to question 10.]	
[If no, no further questions.]	
8. Does the patient have a diagnosis of active ankylosing spondylitis?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If no, skip to question 11.]	
9. Has the patient tried and had insufficient response to an adequate trial of two full dose nonsteroidal anti-inflammatory drug (NSAID) therapies?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If no, no further questions.]	
10. Has the patient tried and had insufficient response with etanercept, adalimumab, or secukinumab?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If yes, skip to question 24.]	
[If no, no further questions.]	
11. Does the patient have a diagnosis of chronic moderate to severe plaque psoriasis?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If no, skip to question 20.]	

12. Does the patient have either of the following: A) body surface area involvement of greater than 10 percent, or B) body surface area involvement of less than or equal to 10 percent, but involves sensitive areas (palms/soles of feet, genitalia and head/neck)?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If no, no further questions.]	
13. Has the patient tried and had insufficient response or contraindication to at least one of the following: A) phototherapy, or B) systemic therapy with methotrexate or cyclosporine?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If no, no further questions.]	
14. Does the patient have moderate disease?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If no, skip to question 16.]	
15. Has the patient had a documented trial and insufficient response to topical pharmacologic therapy (corticosteroids, vitamin D analogues, or retinoids), unless their use is contraindicated?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If no, no further questions.]	
16. Is the patient at least 6 years but less than 18 years of age?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If no, skip to question 18.]	
17. Has the patient tried and had insufficient response to etanercept or secukinumab?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If yes, skip to question 26.]	
[If no, no further questions.]	
18. Is the patient at least 18 years of age or older?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If no, no further questions.]	
19. Has the patient tried and had insufficient response to brodalumab, etanercept, adalimumab, or secukinumab?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If yes, skip to question 26.]	
[If no, no further questions.]	
20. Does the patient have a diagnosis of adult-onset active non-radiographic axial spondyloarthritis (nr-axSpA)?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If no, no further questions.]	
21. Does the patient have objective signs of inflammation indicated by C-reactive protein (CRP) levels above the upper limit of normal OR sacroiliitis on magnetic resonance imaging (MRI)?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	

[If no, no further questions.]	
22. Has the patient tried and had insufficient response to an adequate trial of two full dose nonsteroidal anti-inflammatory drug (NSAID) therapies?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If no, no further questions.]	
23. Has the patient tried and had insufficient response to secukinumab?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If no, no further questions.]	
24. Is the patient 18 years of age or older?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If yes, skip to question 26.]	
[If no, no further questions.]	
25. Is the patient experiencing clinical improvement from treatment as supported by one of the following outcomes: A) reduction in the signs and symptoms, B) prolonged beneficial clinical response, C) inhibition of structural damage progression, or D) improved physical functioning?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If no, no further questions.]	
26. Does the patient have any of the following diagnoses: A) uveitis, B) sarcoidosis, C) graft-versus-host disease, D) interleukin-2 toxicity, E) Langerhans cell histiocytosis, F) myositis, G) nephrotic syndrome, H) amyloidosis, I) periodic fever syndrome, J) renal transplant syndrome, K) moderate to severe Crohn's disease in pediatric patients as first line therapy or L) definitive radiographic axial spondyloarthritis with evidence of structural damage on sacroiliac joints?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If yes, no further questions.]	
27. Is the requested drug being prescribed for FDA-approved dosages and dosing intervals?	<input type="checkbox"/> Y <input type="checkbox"/> N
NOTE: Submission of medical records is required.	
[If no, no further questions.]	
28. Will the requested drug be used concurrently with another biologic disease-modifying anti-rheumatic drug (DMARD)?	<input type="checkbox"/> Y <input type="checkbox"/> N

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date